Determinants of recovery from severe posterior reversible encephalopathy syndrome

Stephane Legriel, Olivier Schraub, Elie Azoulay, Philippe Hantson, Eric Magalhaes, Isaline Coquet, Cedric Bretonniere, Olivier Gilhodes, Nadia Anguel, Bruno Megarbane, Laurent Benayoun, David Schnell, Gaetan Plantefeve, Julien Charpentier, Laurent Argaud, Bruno Mourvillier, Arnaud Galbois, Ludivine Chalumeau-Lemoine, Michel Rivoal, François Durand, Arnaud Geffroy, Marc Simon, Annabelle Stoclin, Jean-Louis Pallot, Charlotte Arbelot, Martine Nyunga, Olivier Lesieur, Gilles Troché, Fabrice Bruneel, Yves-Sébastien Cordoliani, Jean-Pierre Bedos, Fernando Pico, Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS), Pierre Guezennec, Sybille Merceron, Matthieu Henry Lagarrigue, Benjamin Planquette, Pierrick Cronier, Pierrick Cronier, Virginie Laurent, Julia Hilly-Ginoux, Christian Hubert, Thierry Duprez, Emmanuel Canet, Virginie Lemiale, Benoit Schlemmer, Jacques Frija, Charles Cerf, Antoine Scherrer, Frederic Bourdain, Marie-Laure Chadenat, Chantal-Nifle, Anne-Celine Zeghoudi, Melissa Tir, Manuela Vasile, Christian Richard, Denis Ducreux, Frederic Baud, Jean-Pierre Guichard, Dominique Hervé, Emmanuel Houdart, Jean Mantz, Hervé Mentec, Jean-Paul Mira, Franck Pilleul, Martin Cour, Michel Wolff, Isabelle Klein, Bertrand Guidet, Elisabeth Auffray-Calvier, Hubert Desal, Sandrine Wiertlewski, Benoit Guillon, Muriel Fartoukh, Gerard Vermeulin, Jean-Bernard D'Harcourt, François Blot, Clarisse Dromain, Vincent Das, Jean-Jacques Rouby, Damien Gallanaud, Denis Lacroix, Stephane Silvera, Betty Marro, Paul Muresan, Sanaa El Mouhadi, Anne Liesse, Emmanuel Michelin, Stephane Legriel, Olivier Schraub, Elie Azoulay, Philippe Hantson, Eric Magalhaes, Isaline Coquet, Cedric Bretonniere, Olivier Gilhodes, Nadia Anguel, Bruno Megarbane, Laurent Benayoun, David Schnell, Gaetan Plantefeve, Julien Charpentier, Laurent Argaud, Bruno Mourvillier, Arnaud Galbois, Ludivine Chalumeau-Lemoine, Michel Rivoal, François Durand, Arnaud Geffroy, Marc Simon, Annabelle Stoclin, Jean-Louis Pallot, Charlotte Arbelot, Martine Nyunga, Olivier Lesieur, Gilles Troché, Fabrice Bruneel, Yves-Sébastien Cordoliani, Jean-Pierre Bedos, Fernando Pico, Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS), Pierre Guezennec, Sybille Merceron, Matthieu Henry Lagarrigue, Benjamin Planquette, Pierrick Cronier, Pierrick Cronier, Virginie Laurent, Julia Hilly-Ginoux, Christian Hubert, Thierry Duprez, Emmanuel Canet, Virginie Lemiale, Benoit Schlemmer, Jacques Frija, Charles Cerf, Antoine Scherrer, Frederic Bourdain, Marie-Laure Chadenat, Chantal-Nifle, Anne-Celine Zeghoudi, Melissa Tir, Manuela Vasile, Christian Richard, Denis Ducreux, Frederic Baud, Jean-Pierre Guichard, Dominique Hervé, Emmanuel Houdart, Jean Mantz, Hervé Mentec, Jean-Paul Mira, Franck Pilleul, Martin Cour, Michel Wolff, Isabelle Klein, Bertrand Guidet, Elisabeth Auffray-Calvier, Hubert Desal, Sandrine Wiertlewski, Benoit Guillon, Muriel Fartoukh, Gerard Vermeulin, Jean-Bernard D'Harcourt, François Blot, Clarisse Dromain, Vincent Das, Jean-Jacques Rouby, Damien Gallanaud, Denis Lacroix, Stephane Silvera, Betty Marro, Paul Muresan, Sanaa El Mouhadi, Anne Liesse, Emmanuel Michelin

Abstract

Objective: Few outcome data are available about posterior reversible encephalopathy syndrome (PRES). We studied 90-day functional outcomes and their determinants in patients with severe PRES.

Design: 70 patients with severe PRES admitted to 24 ICUs in 2001-2010 were included in a retrospective cohort study. The main outcome measure was a Glasgow Outcome Scale (GOS) of 5 (good recovery) on day 90.

Main results: Consciousness impairment was the most common clinical sign, occurring in 66 (94%) patients. Clinical seizures occurred in 57 (81%) patients. Median mean arterial pressure was 122 (105-143) mmHg on scene. Cerebral imaging abnormalities were bilateral (93%) and predominated in the parietal (93%) and occipital (86%) white matter. Median number of brain areas involved was 4 (3-5). Imaging abnormalities resolved in 43 (88%) patients. Ischaemic and/or haemorrhagic complications occurred in 7 (14%) patients. The most common causes were drug toxicity (44%) and hypertensive encephalopathy (41%). On day 90, 11 (16%) patients had died, 26 (37%) had marked functional impairments (GOS, 2 to 4), and 33 (56%) had a good recovery (GOS, 5). Factors independently associated with GOS<5 were highest glycaemia on day 1 (OR, 1.22; 95%CI, 1.02-1.45, p = 0.03) and time to causative-factor control (OR, 3.3; 95%CI, 1.04-10.46, p = 0.04), whereas GOS = 5 was associated with toxaemia of pregnancy (preeclampsia/eclampsia) (OR, 0.06; 95%CI, 0.01-0.38, p = 0.003).

Conclusions: By day 90 after admission for severe PRES, 44% of survivors had severe functional impairments. Highest glycaemia on day 1 and time to causative-factor control were strong early predictors of outcomes, suggesting areas for improvement.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Patient flow chart, clinicoradiologic features,…
Figure 1. Patient flow chart, clinicoradiologic features, management, and 90-day follow-up in 70 patients with severe posterior reversible encephalopathy syndrome.
¥ Hypertension was defined according to the 2007 European guidelines for the management of arterial hypertension(16). Grade 1: mild hypertension (systolic blood pressure [SBP], 140–159 mmHg and/or diastolic blood pressure [DBP], 90–99 mmHg); Grade 2: moderate hypertension (SBP, 160–179 mmHg and/or DBP, 100–109 mmHg); Grade 3: severe hypertension (SBP≥180 mmHg and/or DBP≥110 mmHg) ‡ Mean arterial pressure (2/3 diastolic +1/3 systolic pressure) § Nine patients with haemorrhagic complications at first imaging: 3 with no follow-up imaging studies, 3 with persistent haemorrhagic abnormalities by follow-up imaging, and 3 with resolution of the haemorrhagic abnormalities Ψ According to the Logistic Organ Dysfunction (LOD) score †The primary outcome measure was the score on the Glasgow Outcome Scale (GOS) 90 days after onset of severe posterior reversible encephalopathy syndrome. A score of 1 indicates death; 2, a vegetative state (the patient is unable to interact with the environment); 3, severe disability (the patient is unable to live independently but can follow commands); 4, moderate disability (the patient is capable of living independently but unable to return to work or school); and 5, mild or no disability (the patient is able to return to work or school). A favourable outcome was defined as a score of 5 and an unfavourable outcome as a score lower than 5. The day-90 GOS score was known in all 70 patients.

References

    1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, et al. (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334: 494–500.
    1. Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, et al. (1992) Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 159: 379–383.
    1. Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, et al. (1995) Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 165: 627–631.
    1. Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 29: 1036–1042.
    1. Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29: 1043–1049.
    1. Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28: 1320–1327.
    1. Legriel S, Pico F, Azoulay E (2011) Understanding Posterior Reversible Encephalopathy Syndrome. In: Vincent J-L, editor. Annual Update in Intensive Care and Emergency Medicine 2011: Springer Berlin Heidelberg. 631–653.
    1. Burnett MM, Hess CP, Roberts JP, Bass NM, Douglas VC, et al... (2010) Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors. Clin Neurol Neurosurg.
    1. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA (2008) Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 65: 205–210.
    1. Servillo G, Striano P, Striano S, Tortora F, Boccella P, et al. (2003) Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients. Intensive Care Med 29: 2323–2326.
    1. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA (2007) Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 69: 894–897.
    1. Legriel S, Merceron S, Pico F, Cordoliani YS, Bedos JP (2011) A rare cause of status epilepticus. Intensive Care Med.
    1. Legriel S, Bruneel F, Spreux-Varoquaux O, Birenbaum A, Chadenat ML, et al. (2008) Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus. Neurocrit Care 9: 247–252.
    1. Teasdale G, Jennett B (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet 2: 81–84.
    1. Bateman DE (2001) Neurological assessment of coma. J Neurol Neurosurg Psychiatry 71 Suppl 1i13–17.
    1. Wippold FJ Jr (2008) Focal neurologic deficit. AJNR Am J Neuroradiol 29: 1998–2000.
    1. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, et al. (2001) A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 345: 631–637.
    1. Lowenstein DH, Bleck T, Macdonald RL (1999) It’s time to revise the definition of status epilepticus. Epilepsia 40: 120–122.
    1. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, et al. (2002) Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 59: 205–210.
    1. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, et al. (1998) A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 339: 792–798.
    1. Treiman DM, Walton NY, Kendrick C (1990) A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res 5: 49–60.
    1. Kaplan PW (2006) The EEG of status epilepticus. J Clin Neurophysiol 23: 221–229.
    1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462–1536.
    1. Legriel S, Azoulay E, Resche-Rigon M, Lemiale V, Mourvillier B, et al. (2010) Functional outcome after convulsive status epilepticus. Crit Care Med 38: 2295–2303.
    1. Vaughan CJ, Delanty N (2000) Hypertensive emergencies. Lancet 356: 411–417.
    1. Le GallJR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957–2963.
    1. Le GallJR, Klar J, Lemeshow S, Saulnier F, Alberti C, et al. (1996) The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 276: 802–810.
    1. Jennett B, Teasdale G, Braakman R, Minderhoud J, Knill-Jones R (1976) Predicting outcome in individual patients after severe head injury. Lancet 1: 1031–1034.
    1. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, et al. (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 189: 904–912.
    1. Casey SO, Sampaio RC, Michel E, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21: 1199–1206.
    1. Servillo G, Bifulco F, De Robertis E, Piazza O, Striano P, et al. (2007) Posterior reversible encephalopathy syndrome in intensive care medicine. Intensive Care Med 33: 230–236.
    1. Mueller-Mang C, Mang T, Pirker A, Klein K, Prchla C, et al. (2009) Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance? Neuroradiology 51: 373–383.
    1. Godoy DA, Di Napoli M, Rabinstein AA (2010) Treating hyperglycemia in neurocritical patients: benefits and perils. Neurocrit Care 13: 425–438.
    1. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32: 2426–2432.
    1. Garg R, Chaudhuri A, Munschauer F, Dandona P (2006) Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke 37: 267–273.
    1. Fogelholm R, Murros K, Rissanen A, Avikainen S (2005) Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatry 76: 349–353.
    1. Jeremitsky E, Omert LA, Dunham CM, Wilberger J, Rodriguez A (2005) The impact of hyperglycemia on patients with severe brain injury. J Trauma 58: 47–50.
    1. Sala F, Menna G, Bricolo A, Young W (1999) Role of glycemia in acute spinal cord injury. Data from a rat experimental model and clinical experience. Ann N Y Acad Sci 890: 133–154.
    1. Wilson JT, Pettigrew LE, Teasdale GM (1998) Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma 15: 573–585.
    1. de Gans J, van de Beek D (2002) Dexamethasone in adults with bacterial meningitis. N Engl J Med 347: 1549–1556.
    1. Todd MM, Hindman BJ, Clarke WR, Torner JC (2005) Mild intraoperative hypothermia during surgery for intracranial aneurysm. N Engl J Med 352: 135–145.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi